合一 (4743.TWO)

152.50 +3.00 (+2.01%) 收市：01:30PM CST

合一

No.236, Xinyi Road
11th Floor Sec. 4 Da’an district
Taipei 106
Taiwan
886 2 2703 1098
https://www.onenessbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Nien-Yi Chen	Deputy General Manager of Antibody New Drug Division;	6.03M	無	無
Ms. Shuling Cheng Ph.D.	President	無	無	無
Ms. Wen-Tzu Hsiao	Acting Spokesperson & Senior Manager of Finance Department	無	無	無
Wen Ci Xiao	Accounting Supervisor	無	無	無
Dr. Jui-Ching Chen Ph.D.	Director of New Drug Development Department	無	無	無
Mr. Kung-Ming Lu	Director of Operation Center	無	無	無
Mr. Tzu-Chun Yang	Associate General Manager of Information Technology Department	2.14M	無	無

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase I clinical trials; and FB918 for the treatment of asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.

公司管治

截至 無 止，合一 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。